loading...| Preferred Name |
paritaprevir |
| Synonyms |
ABT450 |
| ID |
http://purl.bioontology.org/ontology/MESH/C585405 |
| altLabel |
ABT450 paritaprevir hydrate ABT-450 veruprevir anhydrous ABT 450 (2R,6S,12Z,13aS,14aR,16aS)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazin-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16atetradecahydrocyclopropa(E)pyrrolo(1,2-a)(1,4)diazacyclopentadecine-14a(5H)-carboxamide paritaprevir dihydrate veruprevir |
| cui |
C3883274 C3864824 C3712108 |
| Has mapping qualifier | |
| HM |
D003521 D011392/Q000031 D013449 D047029 |
| II |
D000998 |
| Inverse of RB |
HRQ5901O78 OU2YM37K86 0 |
| Mapped to |
http://purl.bioontology.org/ontology/MESH/D047029 http://purl.bioontology.org/ontology/MESH/D013449 |
| MDA |
20140101 |
| MeSH Frequency |
297 |
| MMR |
20220812 |
| notation |
C585405 |
| prefLabel |
paritaprevir |
| RR |
HRQ5901O78 |
| SC |
1 |
| Scope Statement |
inhibits HCV NS3 protease |
| SRC |
World J Gastroenterol. 2013 Jun 7;19(21):3199-206. |
| TERMUI |
T001123447 T852850 T001123450 T001092944 T001092945 T000877905 T001123448 T001123449 T001123446 |
| TH |
NLM (2021) NLM (2015) FDA SRS (2017) USAN (19XX) NLM (2022) NLM (2014) INN (19XX) |
| tui |
T109 T121 |